Peptide library
Immune ResearchSkin / Hair

LL-37

Cathelicidin antimicrobial peptide studied in immune research.

Mechanism Focused

Evidence Level

Moderate

Mechanism7/10
Safety Clarity5/10
Research Popularity5/10

Research Type

In vitroAnimal

/ System Mapping

Where this compound appears in research pathways

Research-only note: This mapping is educational and does not represent a treatment protocol.

/ 01

Overview

Cathelicidin antimicrobial peptide studied in immune research.

/ 02

Mechanism of Action

Studied for antimicrobial activity and immune modulation.

/ 03

Research Applications

Antimicrobial and inflammatory pathway research.

Studied for, research explores, preclinical models suggest, clinical studies have investigated.

/ 04

Studied Research Contexts

In vitroAnimal

/ 05

Studied Research Dosing Ranges

Limited public data on dosing ranges across research models.

Dosing varies by study design and is not a recommendation for human use.

/ 06

Potential Adverse Effects Reported in Research

Adverse effect data is limited. Many compounds in this database lack human safety profiles.

/ 07

Mechanism Deep Dive

LL-37 is the only human cathelicidin antimicrobial peptide. Research describes broad-spectrum antimicrobial activity, biofilm modulation, immune cell signaling, and roles in inflammation and wound-healing biology.

/ 08

Pathway Role

Sits within innate immunity and antimicrobial defense pathways, with crosstalk into inflammation and wound-healing signaling.

/ 09

Biological Targets

Microbial membranes (broad-spectrum)Biofilm structuresInnate immune cell signalingWound-repair signaling

/ 10

Research Applications

  • Antimicrobial activity research
  • Wound healing models
  • Inflammation modulation research
  • Biofilm research

/ 11

Evidence Summary

Moderate mechanistic and preclinical literature. Controlled human therapeutic outcome data is limited.

Evidence Level Rationale

Rated moderate based on consistency of mechanistic findings across antimicrobial and immune model systems.

/ 12

Research Observation Timeline

Early Signal Window

Antimicrobial and signaling effects within hours in vitro

Primary Study Window

Days to weeks in immune and wound-model studies

Endpoint Type

Antimicrobial, immune, and wound-repair endpoints

Evidence Strength

Moderate mechanistic / preclinical

No reliable general human timeline. Immune/wound-model observation windows only.

/ 13

Safety & Unknowns

Systemic human use is not well-characterized. Off-target immune and inflammatory effects are open research questions.

/ 14

Research Limitations

Translation from mechanistic and wound-model data to general human therapeutic timelines is not established.

/ 15

References

References are being curated from peer-reviewed literature.

/ 07

Evidence Score

Mechanism Confidence7/10
Safety Clarity5/10
Research Popularity5/10

Overall Research Confidence

Moderate

Reflects breadth of mechanism, study type, and reproducibility across research literature.

Appears in pathways

For research and educational purposes only.

Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.